BioAtla Inc (BCAB) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Graphic logo of BioAtla Corp (BCAB)

BioAtla, Inc. (BCAB) develops specific antibodies that activate exclusively within the acidic environment of neoplasms, protecting healthy cells from toxicity. This price action visualized on the GURU.Markets platform shows that the EV/EBITDA ratio is 0.00. The business relies on a closed R&D circuit with high barriers to entry; however, due to the lack of commercial products and its current trial stage, the company lacks a stable cash flow.

BCAB BioAtla: Enterprise Value to Operating Income Before Depreciation in the range 11/23/2025 - 09/06/2026

BCAB (bioatla.com): analytical breakdowns and indicator data

- stock price and consensus target price:
Stock Quotes BioAtla|BCAB - Fair Value Consensus
- market capitalization indicators:
Market Value BCAB|BCAB - Total Enterprise Value
- book value of equity indicators:
Net Assets per Single Share BioAtla|BCAB - Accounting Capitalization|Market Capitalization to Book Value Ratio bioatla.com|BCAB - Cumulative Company Assets
- debt and liquidity data:
Debt to Equity BioAtla, Inc.|BCAB - Long-Term Liabilities to Capital|Short-Term Debt to Equity BioAtla|BCAB - Company Debts|Debt to Book Capitalization Ratio BCAB|BCAB - Long-Term Debt|Company Short-Term Debts BioAtla|Quick Liquidity Indicator bioatla.com
- business earnings and investment ratios data:
BCAB - Company Net Income|Future Profit BioAtla, Inc.|BCAB - Company Value to Net Income|Projected Price to Earnings BioAtla|BCAB - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple BCAB|BCAB - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) BioAtla|BCAB - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months bioatla.com|BCAB - Earnings per share increase in current year|Earnings growth forecast for next year BioAtla, Inc.
Summary company analytics:BCAB (BioAtla Corp)
Original product of BioAtla

The innovative platform of BioAtla, Inc. (BCAB) for creating activatable biologics and its patent authority determine the long-term business value, which is reflected on GURU.Markets by the company's historical EV/EBITDA trend. This ratio correlates the total market value of the asset with its operating profit before taxes and depreciation, allowing investors to assess the real value of the business accounting for debt and determine the asset's undervaluation relative to the sector.

Competitor analysis

Incyte Corp. - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation HCM|NUVB - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA dayonebio.com|Monopar Therapeutics Inc. (MNPR) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation INBX|IMAB (I-Mab Biopharma Co., Ltd.) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Fennec (FENC)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Heron Therapeutics (HRTX)|NVCT - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Coherus BioSciences Inc. CHRS|Corbus Pharmaceuticals Holdings, Inc. - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CRDF - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA BeyondSpring Inc|LIXT: EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple Citius Pharmaceuticals, Inc. CTXR|Enterprise Value to EBITDA Ratio CLRB|Company Value to EBITDA BioLineRx Ltd BLRX|Enterprise Value to EBITDA Ratio CANF (Can-Fite BioPharma, Ltd.)|APRE (aprea.com) - Business Value to Operating Income Before Depreciation|Kazia Therapeutics Limited - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio SLXN (Silexion Therapeutics Corp.)|NuCana Corp - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation CMRX (Chimerix Inc.)|CYCC: EV/EBITDA Multiple|Company Value to EBITDA G1 Therapeutics (GTHX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Kronos Bio, Inc.|KTRA: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ONCT|EV/EBITDA Multiple Portage Biotech Inc (PRTG)